These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 17299170)

  • 1. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 2. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 3. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 4. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 5. Contradictory actions on off-label use of prescription drugs? The FDA and CMS versus the U.S. Justice Department.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2009 Mar; 15(2):161-5. PubMed ID: 19236131
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 7. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 8. Physicians' liability for off-label prescriptions.
    Riley JB; Basilius PA
    Nephrol News Issues; 2007 Jun; 21(7):43-4, 46-7. PubMed ID: 17623984
    [No Abstract]   [Full Text] [Related]  

  • 9. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.
    O'Reilly J; Dalal A
    Ann Health Law; 2003; 12(2):295-324, table of contents. PubMed ID: 12856461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 13. Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.
    Kalb PE; Greenberg PE
    Pharmacoeconomics; 2009; 27(8):623-5. PubMed ID: 19835018
    [No Abstract]   [Full Text] [Related]  

  • 14. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 15. FDAMA 1997 Section 114: another look.
    Jackson J
    Value Health; 2009; 12(2):191-2. PubMed ID: 18657097
    [No Abstract]   [Full Text] [Related]  

  • 16. A much-anticipated FDA reform bill is signed into law: progress and compromise.
    Nissen SE
    Curr Cardiol Rep; 2008 Feb; 10(1):1-2. PubMed ID: 18416992
    [No Abstract]   [Full Text] [Related]  

  • 17. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

  • 18. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 19. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.